This paper responds to the “Questions for Public Comment” (“QFPCs”) posed by the FTC and DOJ (“Agencies”) on September 22, 2009.
What’s 340B? An economist’s view of the recent wave of 340B litigation
But this change has led to complex relationships among pharmaceutical manufacturers, hospitals, pharmacies, and third-party administrators, increasing...

